Skip to content

Effect of Pectointercostal+ESP Block on Postoperatif Analgesia in Open Heart Surgery

Determining to the Effect of Pectointercostal and ESP Block on Postoperative Analgesia During Open Heart Surgery

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05590013
Enrollment
60
Registered
2022-10-21
Start date
2022-11-15
Completion date
2023-08-15
Last updated
2023-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Brief summary

American Society of Anaesthesiologist physical status II-III, aged between 18-65, 60 patients which underwent open cardiac surgery will recruited to this study. These subjects will Ultrasound (USG) guided erector spinae block will perform at T6 level (bilaterally) and pectointercostal plane block at 4-5 intercostal space to the all patient under general anaesthesia. Totally bupivacaine %0.25 2.5 mg/kg will use blocks and 1 ml epinephrin will add to the each local anesthetic solutions. 10 ml %0.25 bupivacain will apply to the chest tube area at the end of surgery. 0.1 microgram/kg morphine will apply intravenously at last 30 minutes of surgery postoperative analgesia to all patients. Postoperative pain assessment will perform with visual analog scale (VAS)

Detailed description

American Society of Anaesthesiologist physical status II-III, aged between 18-65, 60 patients which underwent open cardiac surgery will recruited to this study. The patients were randomly allocated into two groups (1:1), via a computer-generated randomization list. Ultrasound (USG) guided erector spinae block will perform at T6 level (bilaterally) and pectointercostal plane block at 4-5 intercostal space to the 30 patients under general anaesthesia in Group block and block will not perform to the control group. Sevoflurane+remifentanil and O2/air combination will perform to the all patients during the surgery. Totally bupivacaine %0.25 2.5 mg/kg will use for blocks and 1 ml epinephrin will add to the each local anesthetic solutions in each side.10 ml %0.25 bupivacain will apply to the chest tube area at the end of surgery. 0.1 microgram/kg morphine intravenously will apply for postoperative analgesia to the all patients at last 30 minutes of surgery. Postoperative pain assessment will perform with visual analog scale (VAS). VAS, morphine consumption and complications will record.Paracetamol 10 mg/kg will repeat to the all patients at the 12th of postoperative period, intravenously. The patient controlled anesthesia with morphin will apply to the all patients. If the VAS score is higher than 4, the rescue analgesic diclofenac Na 75 mg will administer intravenously.

Interventions

Pectointercostal plane block will apply at the 4-5. intercostal space and ESP block will apply athe T6 level bilaterally

Sponsors

Cukurova University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* ASA II-III patients * The patients who will operate for open heart surgery

Exclusion criteria

* The patients with Coagulopaty * Allergy with local anesthetics * infection at the injection sites * Obesity (BMI \>35kg/m2) * Liver and/or kidney failure

Design outcomes

Primary

MeasureTime frameDescription
Postoperative analgesia24 hours in Postanesthesia care unit (PACU)Visual analog scale (VAS) scores at the postoperative 24th hours. VAS scores define pain scores between 0-10. 0 reflects nopain, 10 reflects the worst pain.
Morphine consumption24 hours in Postanesthesia care unit (PACU)Postoperative morphine consumption during the postoperative 24th hours

Secondary

MeasureTime frameDescription
Ekstübation timeFirst 6 hours at Postanesthesia care unit (PACU)Time between end of the surgery and extubation of the patient

Countries

Turkey (Türkiye)

Contacts

Primary ContactEbru Biricik
ebrubiricik01@gmail.com+905052420223
Backup ContactEbru Biricik
ebrubiricik01@gmail.com+903223386084

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026